Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vernakalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Advanz Pharma
Deal Size : $76.0 million
Deal Type : Acquisition
Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp
Details : Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $76.0 million
May 27, 2020
Lead Product(s) : Vernakalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Advanz Pharma
Deal Size : $76.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?